Prognostic value of myeloid differentiation primary response 88 and toll-like receptor 4 in breast cancer patients

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Ma, Fang Jing ^a,b,c   Liu, Zhe Bin ^a,b   Hu, Xin ^a,b   Ling, Hong ^a,b   Li, Shan ^a,b   Wu, Jiong ^a,b   Shao, Zhi Ming ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TLR4 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR IMMUNITY; AGED; BREAST TUMOR; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOID DIFFERENTIATION FACTOR 88; PROGNOSIS; TOLL-LIKE RECEPTOR 4;

EID: 84909994701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111639     Document Type: Article

References (34)

1. Baselga J, Norton L (2002) Focus on breast cancer. Cancer Cell 1: 319-322.
2. Fan L, Zheng Y, Yu KD, Liu GY, Wu J, et al. (2009) Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat 117: 409-416.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al (2000) Molecular portraits of human breast tumors. Nature 406: 747-752.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
5. Yu H, Kortylewski M, Pardoll D (2007) Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51.
6. Costantini S, Capone F, Guerriero E, Castello G (2009) An approach for understanding the inflammation and cancer relationship. Immunol Lett 126: 91-92.
7. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454: 436-444.
8. de Visser KE, Eichten A, Coussens LM (2006) Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6: 24-37.
9. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867.
10. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388: 394-397.
11. Molteni M, Marabella D, Orlandi C, Rossetti C (2006) Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett 235: 75-83.
12. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, et al. (2007) Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 6: 1704-1709.
13. Yang H, Zhou H, Feng P, Zhou X, Wen H, et al. (2010) Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res 29: 92.
14. Rajput S, Volk-Draper LD, Ran S (2013) TLR4 is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12: 1676-1687.
15. Ren T, Xu L, Jiao S, Wang Y, Cai Y, et al. (2009) TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res 15: 623-630.
16. Vaisanen MR, Vaisanen T, Jukkola-Vuorinen A, Vuopala KS, Desmond R, et al. (2010) Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate 70: 817-824.
17. DeNardo DG, Johansson M, Coussens LM (2008) Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev 27: 11-18.
18. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124: 783-801.
19. Huang B, Zhao J, Li H, He KL, Chen Y, et al. (2005) Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 65: 5009-5014.
20. Ahmed A, Wang JH, Redmond HP (2012) Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann Surg Oncol 20 Suppl 3: S389-396.
21. Li DQ, Wang L, Fei F, Hou YF, Luo JM, et al. (2006) Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trapmass spectrometry. Proteomics 6: 3352-3368.
22. Liang B, Chen R, Wang T, Cao L, Liu Y, et al. (2013) Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma. Clin Cancer Res 19: 2905-2916.
23. van t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
24. Cao AY, He M, Huang L, Shao ZM, Di GH (2013) Clinicopathologic characteristics at diagnosis and the survival of patients with medullary breast carcinoma in China: a comparison with infiltrating ductal carcinoma-not otherwise specified. World J Surg Oncol 11: 91.
25. Cao AY, Huang L, Wu J, Lu JS, Liu GY, et al. (2012) Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J Surg Oncol 10: 152.
26. Galea MH, Blamey RW, Elston CE, Ellis IO (1992) The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 22: 207-219.
27. Carter CL, Allen C, Henson DE (1989) Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 63: 181-187.
28. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, et al. (2009) Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 69: 3105-3113.
29. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, et al. (2006) TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 66: 3859-3868.
30. Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, et al. (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71: 2466-2475.
31. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, et al. (2000) The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 88: 804-813.
32. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
33. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393-10398.
34. Bhattacharya D, Yusuf N (2012) Expression of toll-like receptors on breast tumors: taking a toll on tumor microenvironment. Int J Breast Cancer 2012: Available: http://dx.doi.org/10.1155/2012/716564.